Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Patients with hepatic encephalopathy (HE) suffer from significant symptoms and impaired quality of life. Improved understanding on the potential benefits of first-line HE therapies may aid patient-provider discussions regarding expected benefits of HE treatments. We aimed to perform a systematic review to assess the effects of lactulose and rifaximin on patient-reported outcomes (PROs).
Methods: We searched MEDLINE, EMBASE, and Cochrane Library databases for randomized trials or prospective cohort studies using lactulose and/or rifaximin for the management of HE and assessing changes in PRO using PRO instruments. Physician reviewers independently reviewed titles, abstracts, and full texts and extracted data independently. We performed random-effects meta-analyses to examine the effects of lactulose and rifaximin on PROs.
Results: We identified 16 studies representing 1,376 patients that met inclusion criteria. Most studies assessed treatment of covert HE. In patients with covert HE, lactulose significantly improved overall patient-reported health-related quality of life measured by the Sickness Impact Profile with an estimated pooled mean difference of 6.92 (95% confidence interval: 6.66-7.18) and showed improvements in several subscales. Conversely, rifaximin demonstrated a nonstatistically significant mean difference in the total Sickness Impact Profile of 4.76 (95% confidence interval: -4.23 to 13.76), with strong evidence of heterogeneity between these studies. Studies examining other PRO instruments showed improvements in overall health-related quality of life, social functioning, and sleep from both lactulose and rifaximin.
Discussion: Patients with HE treated with lactulose or rifaximin reported improvements in important PROs. These results may inform provider-patient communication and help manage patient expectations regarding the potential benefits of HE therapies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9904367 | PMC |
| http://dx.doi.org/10.14309/ajg.0000000000002008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hepatitis A-Induced Fulminant Hepatic Failure Linked to Autoimmune Hepatitis in a Child Amidst Diagnostic Challenges of Dengue and Malaria.
Cureus
August 2025
Paediatrics, Farooq Hospital, West Wood Branch, Lahore, Lahore, PAK.
Hepatitis A virus (HAV) typically causes a self-limiting illness in children. Rarely, it can progress to fulminant hepatic failure (FHF), and even less commonly, may be followed by features suggestive of autoimmune hepatitis (AIH). The diagnostic overlap can be particularly challenging in tropical regions, where endemic infections such as dengue and malaria may present with similar clinical features.
View Article and Find Full Text PDFAim: To evaluate the efficacy of combination therapy with rifaximin and CNCM I-745 versus rifaximin monotherapy in patients with small intestinal bacterial overgrowth (SIBO) associated with long-term proton pump inhibitor (PPI) use.
Materials And Methods: A prospective comparative study with two parallel groups was conducted. Eligible patients were those on continuous long-term PPI therapy (> 3 months) with confirmed SIBO.
Adult Left Liver Transplantation With Mesocaval Shunt With Porto-Mesenteric Disconnection: Long-Term Outcome.
Clin Transplant
September 2025
Department of Digestive Diseases, Hôpital Edouard Herriot, Hospices Civils De Lyon, Lyon, France.
Aiming to decrease portal venous pressure and to minimize the risk of small-for-size syndrome when using a partial liver graft for liver transplantation (LT), surgical techniques modulating venous portal inflow have been proposed. We report here our experience on the long-term outcome after adult left split LT with mesocaval shunt (MCS) with porto-mesenteric disconnection (PMD). Between March 1996 and March 2010, 33 adult patients underwent LT from a full-right/full-left SLT for two adult recipients; portal vein inflow modulation through a MCS with PMD was realized in 10 cases.
View Article and Find Full Text PDFEvaluating Clinical Outcomes of Adjunct Rifaximin Therapy in Patients with Overt Hepatic Encephalopathy: A Prospective Randomized Study.
Euroasian J Hepatogastroenterol
June 2025
Department of General Surgery, Maroof International Hospital, Islamabad, Pakistan.
Objectives: This study was conducted to assess the therapeutic benefit of using rifaximin in combination with lactulose vs lactulose alone in the management of overt hepatic encephalopathy (OHE) within a tertiary care setting.
Methods: A randomized controlled trial was conducted with 132 adult patients diagnosed with decompensated liver cirrhosis and presenting with OHE of West Haven Criteria grade II or higher. Participants were randomly allocated to receive either combination therapy (CT), comprising rifaximin and lactulose, or lactulose monotherapy (LM).
Therapeutic Duel of Rifaximin Versus Lactulose in Hepatic Encephalopathy: A Systematic Review.
Cureus
June 2025
Medicine, Mayo Hospital, Lahore, PAK.
This systematic review aimed to compare the clinical efficacy of rifaximin versus lactulose in the management of hepatic encephalopathy (HE) by analyzing evidence from randomized controlled trials (RCTs). A comprehensive search across major databases identified seven eligible RCTs encompassing 693 adult patients diagnosed with overt or minimal HE. Findings demonstrated that rifaximin is at least as effective as lactulose in reversing HE symptoms, with some studies reporting significantly higher HE reversal rates when rifaximin was used in combination with lactulose (e.
View Article and Find Full Text PDF